Clinical Trials Browser

Unknown × Carcinoma, Hepatocellular × regorafenib × Clear all

NCT05962450 2024-01-16

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05811481 2023-04-13

ROSE

Gastrointestinal

Carcinoma, Hepatocellular

NCT05048017 2023-03-29

Regorafenib Combined With PD-1 Inhibitor Therapy for Second-line Treatment of Hepatocellular Carcinoma

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT03475953 2023-03-03

REGOMUNE

Phase 1/2 Unknown

BreastEndocrineGastrointestinalGenitourinaryHead & NeckNETOther solid neoplasmSarcomaThoracic

Gastro-enteropancreatic neuroendocrine tumor, Turcot syndrome, Tertiary Lymphoid Structures, Mesothelioma, Malignant, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Thyroid Neoplasms, Triple Negative Breast Neoplasms

NCT05557656 2022-12-29

A Real World Study of Regogfinib in HCC

Gastrointestinal

Carcinoma, Hepatocellular

NCT04718909 2022-11-10

REGSIN

Phase 2 Unknown

Gastrointestinal

Carcinoma, Hepatocellular

NCT05233358 2022-02-10

HAIC Combined With Second-line "Target Immunity" for HCC With TACE Standard Treatment Low Response or Failure

Phase NA Unknown

Gastrointestinal

Carcinoma, Hepatocellular